prikaz prve stranice dokumenta Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
  Download
PDF 886.81 KB
Scientific paper - Original scientific paper
Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
Vaccines, 10 (2022), 11; 1813. https://doi.org/10.3390/vaccines10111813
Zember, Sanja; Bodulić, Kristian; Balent, Nataša Cetinić; Mikulić, Radojka; Markotić, Alemka; Đaković Rode, Oktavija

Linked objects
COVID-19 (zbirka 2.) | Virtual collection

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Zember, S., Bodulić, K., Balent, N. C., Mikulić, R., Markotić, A. & Đaković Rode, O. (2022). Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines, 10. (11). doi: 10.3390/vaccines10111813

Zember, Sanja, et al. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines, vol. 10, no. 11, 2022. https://doi.org/10.3390/vaccines10111813

Zember, Sanja, Kristian Bodulić, Nataša Cetinić Balent, Radojka Mikulić, Alemka Markotić and Oktavija Đaković Rode. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines 10, no. 11 (2022). https://doi.org/10.3390/vaccines10111813

Zember, S., et al. (2022) 'Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination', Vaccines, 10(11). doi: 10.3390/vaccines10111813

Zember S, Bodulić K, Balent NC, Mikulić R, Markotić A, Đaković Rode O. Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines [Internet]. 2022 October 28 [cited 2024 November 09];10(11). doi: 10.3390/vaccines10111813

S. Zember, K. Bodulić, N. C. Balent, R. Mikulić, A. Markotić and O. Đaković Rode, "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination", Vaccines, vol. 10, no. 11, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:675710. [Accessed: 09 November 2024]

Metadata
Title (english)Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
AuthorSanja Zember
AuthorKristian Bodulić
AuthorNataša Cetinić Balent
AuthorRadojka Mikulić
AuthorAlemka Markotić
AuthorOktavija Đaković Rode
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Anti-SARS-CoV-2 IgG titer decreases rapidly after primovaccination, leading to a mandatory booster vaccination. We analysed anti-SARS-CoV-2 Spike RBD IgG levels (positive ≥ 50 AU/mL) in 405 healthcare workers (3010 sera) who received a booster dose (BD) 9 months after two-dose BNT162b2 primovaccination. Median antibody titer at the time of BD (582.6 AU/mL) was 1.7-fold and 16.4-fold lower than the peak titer after the first (961.5 AU/mL) and the second vaccine dose (SVD) (10,232.6 AU/mL), respectively. One month after vaccination, IgG titer increased 40.6-fold after BD compared with a 10.8-fold increase after primovaccination. Three months after vaccination, post-booster antibodies decreased significantly slower (2.2-fold) than after primovaccination (3.3-fold). At six months, antibodies decreased slower after BD (4.5-fold; median 5556.0 AU/mL) than after primovaccination (9.6-fold; median 1038.5 AU/mL). Antibody titers before and one month after BD correlated weakly (r = 0.30) compared with a strong correlation (r = 0.65) between the corresponding post-primovaccination titers. Pre-vaccination COVID-19 had no effect on IgG levels after BD compared with a positive effect after primovaccination. Despite high post-booster IgG levels, 22.5% of participants contracted mild COVID-19. The trend of IgG decline indicates the need for further revaccination, but the vaccine type should be defined according to viral mutations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleVaccines
Numberingvol. 10, no. 11, 1813
e-ISSN2076-393X
DOIhttps://doi.org/10.3390/vaccines10111813
URN:NBNurn:nbn:hr:184:675710
Publication2022-10-28
ProjectNumber: KK.011.1.01.0006
Title (english): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Leader: Stipan Jonjić
Jurisdiction: Croatia
ProjectNumber: N/A
Title (croatian): Centar izvrsnosti za virusnu imunologiju i cjepiva
Title (english): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Acronym: CERVirVac
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZCI
Document URLhttps://www.mdpi.com/2076-393X/10/11/1813
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-12-09 08:35:04